Continuous dopaminergic stimulation: Is it the answer to the motor complications of levodopa?
2007; Wiley; Volume: 23; Issue: 7 Linguagem: Inglês
10.1002/mds.21819
ISSN1531-8257
Autores Tópico(s)Botulinum Toxin and Related Neurological Disorders
ResumoMovement DisordersVolume 23, Issue 7 p. 1062-1063 Letter to the Editor Continuous dopaminergic stimulation: Is it the answer to the motor complications of levodopa? Mario Zappia MD, Corresponding Author Mario Zappia MD [email protected] Department of Neurosciences, University of Catania, ItalyDepartment of Neurosciences, Policlinico Universitario, Via Santa Sofia 78, 95123 Catania, ItalySearch for more papers by this authorAldo Quattrone MD, Aldo Quattrone MD Institute of Neurology, University “Magna Graecia”, Catanzaro, ItalySearch for more papers by this author Mario Zappia MD, Corresponding Author Mario Zappia MD [email protected] Department of Neurosciences, University of Catania, ItalyDepartment of Neurosciences, Policlinico Universitario, Via Santa Sofia 78, 95123 Catania, ItalySearch for more papers by this authorAldo Quattrone MD, Aldo Quattrone MD Institute of Neurology, University “Magna Graecia”, Catanzaro, ItalySearch for more papers by this author First published: 09 November 2007 https://doi.org/10.1002/mds.21819Citations: 2Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Nutt JG. Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa? Mov Disord 2007; 22: 1–9. 2 Zappia M, Bosco D, Plastino M, et al. Pharmacodynamics of the long-duration response to levodopa in PD. Neurology 1999; 53: 557–560. 3 Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: Imposing pharmacological law and order. Ann Neurol 1996; 39: 561–573. 4 Zappia M, Colao R, Montesanti R, et al. Long-duration to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease. Ann Neurol 1997; 42: 245–248. 5 Zappia M, Oliveri RL, Montesanti R, et al. Loss of long-duration response to levodopa over time in PD. Implications for wearing-off. Neurology 1999; 52: 763–767. 6 Zappia M, Oliveri RL, Bosco D, et al. The long-duration response to L-dopa in the treatment of early PD. Neurology 2000; 54: 1910–1915. 7 Quattrone A, Zappia M, Aguglia U, et al. The Subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann Neurol 1995; 38: 389–395. 8 Quattrone A, Zappia M. Oral pulse levodopa therapy in mild Parkinson's disease. Neurology 1993; 43: 1161–1166. Citing Literature Volume23, Issue715 May 2008Pages 1062-1063 ReferencesRelatedInformation
Referência(s)